AZN - AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)

2024-02-21 11:51:31 ET

Summary

• AstraZeneca PLC has announced a deal to acquire Gracell Biotechnologies Inc., a Chinese company focused on developing cell therapies for cancer and autoimmune diseases.
• The terms of the acquisition include a cash payment of $10 per Gracell ADR and a potential milestone payment of $1.5 per ADR.
• The broad CVR agreement allows multiple ways for AstraZeneca to cash in on the full CVR, increasing the potential value of the acquisition.

Near the end of December 2023, pharmaceutical giant AstraZeneca PLC (AZN) announced a deal to acquire Gracell Biotechnologies Inc. ( GRCL ). Gracell is a Nasdaq-traded Chinese company focused on developing cell therapies for cancer and autoimmune diseases....

For further details see: